| 000 | 01845 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515035734.0 | ||
| 264 | 0 | _c20061218 | |
| 008 | 200612s 0 0 eng d | ||
| 022 | _a0959-8049 | ||
| 024 | 7 |
_a10.1016/j.ejca.2006.05.021 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKouwenhoven, Mathilde C M | |
| 245 | 0 | 0 |
_a1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. _h[electronic resource] |
| 260 |
_bEuropean journal of cancer (Oxford, England : 1990) _cOct 2006 |
||
| 300 |
_a2499-503 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xtherapeutic use |
| 650 | 0 | 4 |
_aBrain Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aChromosomes, Human, Pair 1 |
| 650 | 0 | 4 | _aChromosomes, Human, Pair 19 |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 |
_aDacarbazine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Situ Hybridization, Fluorescence |
| 650 | 0 | 4 | _aMulticenter Studies as Topic |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdrug therapy |
| 650 | 0 | 4 |
_aOligodendroglioma _xdrug therapy |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTemozolomide |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKros, Johan M | |
| 700 | 1 | _aFrench, Pim J | |
| 700 | 1 | _aBiemond-ter Stege, Elize M | |
| 700 | 1 | _aGraveland, Wilfried J | |
| 700 | 1 | _aTaphoorn, Martin J B | |
| 700 | 1 | _aBrandes, Alba A | |
| 700 | 1 | _avan den Bent, Martin J | |
| 773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 42 _gno. 15 _gp. 2499-503 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejca.2006.05.021 _zAvailable from publisher's website |
| 999 |
_c16501333 _d16501333 |
||